Sign In
Buy INBS
$1.96
-0.0200 (-1.01%)
At Close: Aug 10, 2026
Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements
08:30am, Tuesday, 13'th May 2025
20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nin
Intelligent Bio Solutions Drives Global Growth Through Multilingual Digital Expansion
08:30am, Tuesday, 06'th May 2025
Arabic, Italian, and Spanish-language websites unlock commercial access to regions representing over 1.4 billion people Multilingual rollout aligns with product readiness and accelerates international
Intelligent Bio Solutions Expands Global Reach with Latin American Spanish Language Integration into Drug Screening System
08:30am, Tuesday, 22'nd Apr 2025
Company expands Intelligent Fingerprinting Drug Screening System multilingual capabilities to meet growing demand across Latin American Spanish-speaking markets
Intelligent Bio Solutions Expands Middle East Market Reach with Arabic Integration in Drug Screening System
08:30am, Monday, 31'st Mar 2025
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive t
Intelligent Bio Solutions to Highlight Proprietary Drug Testing Technology at 2025 NDASA Conference and Trade Show
08:30am, Friday, 28'th Mar 2025
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing
Intelligent Bio Solutions Stock Drops Despite Key U.S. Patent Win
11:50am, Thursday, 27'th Mar 2025
INBS secures a key U.S. patent, strengthening its IP protection and paving the way for 2025 market entry with innovative biometric technology.
Intelligent Bio Solutions Highlights Continued Expansion with Strategic Partnership in Spain and Andorra
09:00am, Thursday, 27'th Mar 2025
INBS set to capitalize on growing Spanish Drug Testing Market, anticipated to reach $448 million by 2030 Major Spanish accounts currently require 1,000 drug testing cartridges per month NEW YORK, Marc
Intelligent Bio Solutions Secures Key U.S. Patent, Strengthening IP Protection Ahead of Planned 2025 Market Entry
08:30am, Wednesday, 26'th Mar 2025
Company's 6 th U.S. patent adds to comprehensive IP portfolio protecting its unique drug screening technology
Intelligent Bio Solutions' FDA Clearance Process Remains on Track for 2025 U.S. Launch
09:00am, Tuesday, 25'th Mar 2025
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive t
Intelligent Bio Solutions to Expand U.S. IP Portfolio with Expected Patent Grant
08:30am, Thursday, 20'th Mar 2025
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive t
Intelligent Bio Solutions to Participate in the iAccess Virtual Best Ideas Spring Conference on March 25th and 26th
08:30am, Tuesday, 11'th Mar 2025
NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive t
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solution
Intelligent Bio Solutions Inc. Announces Pricing of $2.6 Million Public Offering of Common Stock
08:30am, Thursday, 20'th Feb 2025
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solution
Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock
04:42pm, Wednesday, 19'th Feb 2025
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”) a medical technology company delivering intelligent, rapid, non-invasive testing solutions
Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements
08:30am, Thursday, 13'th Feb 2025
Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-billion dolla
